Shots:

• Sapphire signs a sponsored research agreement with Arizona State University (ASU) to conduct preclinical studies utilizing Quiescin Sulfhydryl Oxidase 1 (QSOX1) inhibitors as anti-neoplastic compounds
• Following the development of its lead anti-metastatic compound- SBI-183- Sapphire collaborates with ASU to synthesize more potent variants inhibiting the enzymatic activity of QSOX1
• Additionally- on Jan 22- 2020- Sapphire collaborated with Skysong Innovations to exclusively license patent rights for cancer technology. The focus of SRA is to utilize the licensed technology to treat cancer by developing potent compounds inhibiting tumor metastasis

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Sapphire Biotech